In a series of studies at McMaster, Dr. Schertzer’s research group demonstrated that treatment with QBECO SSI resulted in a marked reduction in liver fat, inflammation, and fibrosis in fatty liver ...
No treatments currently exist for the fatty liver disease, but the market could be worth $40 billion in less than 10 years. While most interest was shown in Novartis’ oncology pipeline at its ...
Hepatic Disease: A Camu-Camu Fruit Extract to Reduce Liver Fat Aug. 21, 2024 — A research team has shown the benefits of camu-camu on non-alcoholic fatty liver disease. This exotic fruit reduces ...
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...
With the ever-growing life stress and propensity for poor eating habits, the hepato-intestinal system experiences a significant burden. The severity and ...
The new AI model has revealed what humans can expect to look like if we continue with poor eating habits - from yellow eyes and huge bellies, to acne and increased wrinkles ...